De Wikipedia, la enciclopedia libre
Saltar a navegación Saltar a búsquedaMorolimumab es un humano anticuerpo monoclonal contra el humano del factor Rhesus . [1]
Referencias [ editar ]
|
|
|
- Componente de complemento 5
- TNF
- Adalimumab
- Afelimomab
- Certolizumab pegol
- Golimumab
- Infliximab
- Nerelimomab
- Interleucina 5
- Inmunoglobulina E
| - CD3
- Muromonab-CD3
- Otelixizumab
- Teplizumab
- Visilizumab
- CD4
- Clenoliximab
- Keliximab
- Zanolimumab
- CD11a
- CD18
- CD20
- Obinutuzumab
- Rituximab
- Ocrelizumab
- Pascolizumab
- CD23
- CD40
- CD62L / L-selectina
- CD80
- CD147 / Basigin
- CD154
- BLyS
- CTLA-4
- GATO
- Bertilimumab
- Lerdelimumab
- Metelimumab
- Integridad
- Receptor de interleucina-6
- LFA-1
- Receptor de IL-2 / CD25
- Basiliximab
- Daclizumab
- Inolimomab
- Linfocito T ( Zolimomab aritox )
| - Atorolimumab
- Cedelizumab
- Fontolizumab
- Maslimomab
- Morolimumab
- Pexelizumab
- Reslizumab
- Rovelizumab
- Siplizumab
- Talizumab
- Telimomab aritox
- Vapaliximab
- Vepalimomab
|
| - Globulina anti-timocitos
- Globulina anti-linfocitos
|
| - CTLA-4
- Inhibidor de TNF
- Aflibercept
- Alefacept
- Rilonacept
|
|
|
|
- Bermekimab
- Brazikumab
- Briakinumab
- Canakinumab
- Fezakinumab
- Fletikumab
- Guselkumab
- Secukinumab
- Sirukumab
- Tralokinumab †
- Ustekinumab
| - Anrukinzumab
- Bimekizumab †
- Clazakizumab
- Gevokizumab
- Ixekizumab
- Mirikizumab †
- Lebrikizumab
- Olokizumab †
- Perakizumab
- Risankizumab
- Tildrakizumab
| |
|
- Besilesomab
- Fanolesomab ‡
- Lemalesomab
- Sulesomab
|
|
- # OMS-EM
- ‡ Retirado del mercado
- Ensayos clínicos :
- † Fase III
- § Nunca a la fase III
|